- Home
- GVH vs TRAW Comparison
GVH vs TRAW Comparison
Compare GVH & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- TRAW
- Stock Information
- Founded
- GVH 2016
- TRAW 1998
- Country
- GVH Australia
- TRAW United States
- Employees
- GVH N/A
- TRAW N/A
- Industry
- GVH
- TRAW
- Sector
- GVH
- TRAW
- Exchange
- GVH Nasdaq
- TRAW NYSE
- Market Cap
- GVH 10.8M
- TRAW 10.1M
- IPO Year
- GVH 2023
- TRAW 2013
- Fundamental
- Price
- GVH $0.57
- TRAW $2.32
- Analyst Decision
- GVH
- TRAW
- Analyst Count
- GVH 0
- TRAW 0
- Target Price
- GVH N/A
- TRAW N/A
- AVG Volume (30 Days)
- GVH 134.9K
- TRAW 48.8K
- Earning Date
- GVH 02-12-2025
- TRAW 03-31-2025
- Dividend Yield
- GVH N/A
- TRAW N/A
- EPS Growth
- GVH 12.04
- TRAW N/A
- EPS
- GVH 0.09
- TRAW N/A
- Revenue
- GVH $16,540,178.00
- TRAW $226,000.00
- Revenue This Year
- GVH N/A
- TRAW $3.81
- Revenue Next Year
- GVH N/A
- TRAW N/A
- P/E Ratio
- GVH $6.14
- TRAW N/A
- Revenue Growth
- GVH N/A
- TRAW N/A
- 52 Week Low
- GVH $0.47
- TRAW $2.01
- 52 Week High
- GVH $2.57
- TRAW $24.75
- Technical
- Relative Strength Index (RSI)
- GVH 38.53
- TRAW 31.50
- Support Level
- GVH $0.51
- TRAW $2.52
- Resistance Level
- GVH $0.76
- TRAW $2.69
- Average True Range (ATR)
- GVH 0.07
- TRAW 0.27
- MACD
- GVH -0.01
- TRAW 0.08
- Stochastic Oscillator
- GVH 22.76
- TRAW 25.20
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.